Daclatasvir-sofosbuvir combination therapy for chronic hepatitis C virus infection: progress in clinical studies
10.3760/cma.j.issn.1007-3418.2018.02.015
- VernacularTitle: 达拉他韦联合索磷布韦治疗丙型肝炎的临床研究进展
- Author:
Jie LU
1
;
Huijuan ZHOU
;
Qing XIE
Author Information
1. Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China
- Publication Type:Review
- Keywords:
Hepatitis C;
Antiviral agents;
Daclatasvir;
Sofosbuvir
- From:
Chinese Journal of Hepatology
2018;26(2):147-150
- CountryChina
- Language:Chinese
-
Abstract:
All-oral, pan-genotypic combination of direct-acting antiviral agents is currently clinically prescribed trends in the management of chronic hepatitis C virus infection. The combination of daclatasvir and sofosbuvir has proven strong antiviral activity across all common genotypes in clinical trials and real world studies. Furthermore, it can be safely used in patients with advanced liver disease, HCV/HIV co-infection, or HCV recurrence after liver transplantation, more patients will gain clinical benefits. We aim to summarize the clinical progress about this combination.
